Arivan Mahmood Hama

Dr. Arivan Mahmood Hama

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Sulaimani dental journal
Verified
Journal Article
Closed access
LRLazyan Latif Raouf
Lazyan Latif Raouf
KOKawan Othman
Kawan Othman
AHArivan Mahmood Hama
Arivan Mahmood Hama
Objective: This study aims to assess whether repeated attempts at taking alginate impressions improve the manual skills of dental students by measuring the error percentage of each preliminary impression and comparing these percentages across multiple trials to evaluate skill progression. Methods: Twenty dental students from the fifth-year stage were selected randomly to participate in the study. Each student took five alginate impressions after receiving a demonstration that included audio and video presentations to reinforce previously acquired knowledge. Error areas were highlighted using a red pen and then identified and quantified using Adobe Photoshop. Error areas have been deliberately identified to calculate the accuracy of each impression. The null hypothesis was that there would be no significant variation in the error percentages of preliminary impressions across the students' trials. Results: The study's results revealed an improvement in the students' manual skills in taking impressions after repeated trials. Even though the fifth trial had the lowest median error percentage, the difference in group means was not statistically significant. Conclusions: Repeated impression-taking improves dental students' manual skills, lowering error percentages in subsequent trials. Furthermore, the use of digital technologies in dental education facilities breaks skill acquisition down into more straightforward steps to detect and correct the errors.

1 October 2026 in Diseases
Verified
Journal Article
Open access
PDF file
Darya Khalid MahmoodDarya Khalid Mahmood
Darya Khalid Mahmood
AHArivan Mahmood Hama
Arivan Mahmood Hama
Ahmad Shoeb HashmiAhmad Shoeb Hashmi
Ahmad Shoeb Hashmi
Background/Objectives: Understanding the biological role of the receptor activator of nuclear factor-κB ligand (RANK), its ligand (RANKL), and the decoy receptor osteoprotegerin (OPG) is vital for clarifying the pathogenesis of gnathic giant cell-containing lesions and directing targeted clinical treatments. Methods: Following PRISMA 2020 guidelines and a registered PROSPERO protocol [CRD420261461026], we searched PubMed, Scopus, and Web of Science databases for human tissue-level or clinical denosumab studies (2003–2026). Quality was appraised using adapted NOS and JBI checklists. A fixed-effect inverse-variance meta-analysis pooled continuous RANK parameters between aggressive and non-aggressive CGCG subtypes. Results: Eleven primary tissue-marker studies (259 specimens; two previously considered studies were excluded as unpublished, non peer-reviewed sources) and 10 non-overlapping clinical cohorts/case reports (58 patients total: 55 from 7 multi-patient cohorts + 3 single-case reports [Hameed, O’Connell, Kawamura]). Mononuclear stromal cells represent the pathogenetic driver, secreting RANKL to recruit RANK-expressing mature giant cells. Meta-analysis (k = 2 studies) showed that raw membrane RANK-positive cell percentages did not differ significantly between aggressive and non-aggressive phenotypes (pooled Hedges’ g = 0.25, 95% CI −0.29–0.80, p = 0.36), while non-aggressive lesions showed a borderline, non-significant trend toward higher staining intensity-distribution (SID) scores (g = 0.55, 95% CI −0.00–1.11, p = 0.0506). Because this 95% CI crosses zero, and only two studies (k = 2) were pooled, this represents a non-significant trend rather than a statistically confirmed difference between aggressive and non-aggressive CGCG; both pooled estimates are, therefore, hypothesis-generating only. In clinical cohorts, denosumab achieved objective clinical and radiological tumor responses in all reported cases, enabling downstaging from disfiguring resection to conservative curettage. However, post-cessation recurrence was frequent, ranging from 37% in adults to 100% in pediatric cohorts, with pediatric patients at risk of rebound hypercalcemia. Conclusions: The RANK/RANKL/OPG axis, driven by RANKL-secreting mononuclear stromal cells, underlies osteolytic activity in gnathic giant cell lesions. Denosumab is an effective neoadjuvant bridge to jaw-preserving surgery but is not curative; a RANKL-independent, OPG-resistant SOFAT pathway has been hypothesized as one possible contributor to treatment failure, although this proposal is derived from a single external study and requires independent validation before any clinical inference is drawn. Close post-treatment metabolic and radiographic surveillance is warranted in pediatric patients. Prospective studies are needed to define optimal weaning protocols.